Patient characteristics
| Characteristic, n (%) . | All patients (n = 20) . | BTKi naïve (n = 10) . | BTKi exposed (n = 10) . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 66 (41-74) | 60 (46-72) | 69 (41-74) |
| Sex | |||
| Male | 15 (75%) | 7 (70%) | 8 (80%) |
| Female | 5 (25%) | 3 (30%) | 2 (20%) |
| Stage | |||
| II | 5 (26%) | 4 (44%) | 1 (10%) |
| III | 1 (5%) | 1 (11%) | 0 (0%) |
| IV | 13 (68%) | 4 (44%) | 9 (90%) |
| Missing | 1 | 1 | 0 |
| TMTV | |||
| Median, cm3 (range) | 166 (0-1520) | 145 (0-468) | 169 (20-1520) |
| Missing, n | 1 | 1 | 0 |
| Bone marrow involvement | |||
| Involved | 11 (58%) | 4 (40%) | 7 (78%) |
| Not involved | 8 (42%) | 6 (60%) | 2 (22%) |
| Missing | 1 | 0 | 1 |
| ECOG | |||
| 0 | 14 (70%) | 7 (70%) | 7 (70%) |
| 1 | 6 (30%) | 3 (30%) | 3 (30%) |
| Histology | |||
| Pleomorphic | 5 (25%) | 4 (40%) | 1 (10%) |
| Blastoid | 3 (15%) | 2 (20%) | 1 (10%) |
| Ki67% | |||
| <30% | 5 (29%) | 0 (0%) | 5 (71%) |
| >=30% | 12 (71%) | 10 (100%) | 2 (29%) |
| Missing | 3 | 0 | 3 |
| sMIPI score category | |||
| Low risk (<5.7) | 9 (47%) | 6 (67%) | 3 (30%) |
| Intermediate risk (5.7 to <6.2) | 8 (42%) | 3 (33%) | 5 (50%) |
| High risk (≥6.2) | 2 (11%) | 0 (0%) | 2 (20%) |
| Missing | 1 | 1 | 0 |
| TP53 status | |||
| Deleted | 8 (40%) | 3 (30%) | 5 (50%) |
| Mutated | 8 (40%) | 3 (30%) | 5 (50%) |
| Both deleted and mutated | 7 (35%) | 2 (20%) | 5 (50%) |
| Not assessed (molecular) | 2 (10%) | 1 (10%) | 1 (10%) |
| Median number of prior therapies, n (range) | 2 (1-5) | 1 (1-2) | 3 (2-5) |
| Number of prior therapies | |||
| 1 | 9 (45%) | 9 (90%) | 0 (0%) |
| 2 | 5 (25%) | 1 (10%) | 4 (40%) |
| 3+ | 6 (30%) | 0 (0%) | 6 (60%) |
| POD24 after initial therapy | 13 (65%) | 6 (60%) | 7 (70%) |
| Refractory to most recent line of therapy | 10 (50%) | 1 (10%) | 9 (90%) |
| Prior therapy, n (%) | |||
| Rituximab | 19 (95%) | 10 (100%) | 9 (90%) |
| Bendamustine | 3 (15%) | 1 (10%) | 2 (20%) |
| Anthracycline | 17 (85%) | 9 (90%) | 8 (80%) |
| Cytarabine | 16 (80%) | 8 (80%) | 8 (80%) |
| Autologous transplant | 11 (55%) | 7 (70%) | 4 (40%) |
| Venetoclax | 4 (20%) | 0 (0%) | 4 (20%) |
| BTK inhibitor/s∗ | 10 (50%) | 0 (0%) | 10 (100%) |
| Characteristic, n (%) . | All patients (n = 20) . | BTKi naïve (n = 10) . | BTKi exposed (n = 10) . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 66 (41-74) | 60 (46-72) | 69 (41-74) |
| Sex | |||
| Male | 15 (75%) | 7 (70%) | 8 (80%) |
| Female | 5 (25%) | 3 (30%) | 2 (20%) |
| Stage | |||
| II | 5 (26%) | 4 (44%) | 1 (10%) |
| III | 1 (5%) | 1 (11%) | 0 (0%) |
| IV | 13 (68%) | 4 (44%) | 9 (90%) |
| Missing | 1 | 1 | 0 |
| TMTV | |||
| Median, cm3 (range) | 166 (0-1520) | 145 (0-468) | 169 (20-1520) |
| Missing, n | 1 | 1 | 0 |
| Bone marrow involvement | |||
| Involved | 11 (58%) | 4 (40%) | 7 (78%) |
| Not involved | 8 (42%) | 6 (60%) | 2 (22%) |
| Missing | 1 | 0 | 1 |
| ECOG | |||
| 0 | 14 (70%) | 7 (70%) | 7 (70%) |
| 1 | 6 (30%) | 3 (30%) | 3 (30%) |
| Histology | |||
| Pleomorphic | 5 (25%) | 4 (40%) | 1 (10%) |
| Blastoid | 3 (15%) | 2 (20%) | 1 (10%) |
| Ki67% | |||
| <30% | 5 (29%) | 0 (0%) | 5 (71%) |
| >=30% | 12 (71%) | 10 (100%) | 2 (29%) |
| Missing | 3 | 0 | 3 |
| sMIPI score category | |||
| Low risk (<5.7) | 9 (47%) | 6 (67%) | 3 (30%) |
| Intermediate risk (5.7 to <6.2) | 8 (42%) | 3 (33%) | 5 (50%) |
| High risk (≥6.2) | 2 (11%) | 0 (0%) | 2 (20%) |
| Missing | 1 | 1 | 0 |
| TP53 status | |||
| Deleted | 8 (40%) | 3 (30%) | 5 (50%) |
| Mutated | 8 (40%) | 3 (30%) | 5 (50%) |
| Both deleted and mutated | 7 (35%) | 2 (20%) | 5 (50%) |
| Not assessed (molecular) | 2 (10%) | 1 (10%) | 1 (10%) |
| Median number of prior therapies, n (range) | 2 (1-5) | 1 (1-2) | 3 (2-5) |
| Number of prior therapies | |||
| 1 | 9 (45%) | 9 (90%) | 0 (0%) |
| 2 | 5 (25%) | 1 (10%) | 4 (40%) |
| 3+ | 6 (30%) | 0 (0%) | 6 (60%) |
| POD24 after initial therapy | 13 (65%) | 6 (60%) | 7 (70%) |
| Refractory to most recent line of therapy | 10 (50%) | 1 (10%) | 9 (90%) |
| Prior therapy, n (%) | |||
| Rituximab | 19 (95%) | 10 (100%) | 9 (90%) |
| Bendamustine | 3 (15%) | 1 (10%) | 2 (20%) |
| Anthracycline | 17 (85%) | 9 (90%) | 8 (80%) |
| Cytarabine | 16 (80%) | 8 (80%) | 8 (80%) |
| Autologous transplant | 11 (55%) | 7 (70%) | 4 (40%) |
| Venetoclax | 4 (20%) | 0 (0%) | 4 (20%) |
| BTK inhibitor/s∗ | 10 (50%) | 0 (0%) | 10 (100%) |
ECOG, Eastern Cooperative Oncology Group performance status; sMIPI, secondary mantle cell international prognostic index; POD24, progression of disease within 24 months.
Seven patients had previously received ibrutinib alone, 1 patient had previously received ibrutinib and pirtobrutinib, 1 patient had previously received zanubrutinib and pirtobrutinib, and 1 patient had previously received TG-1701 and ibrutinib.